Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Navigation/Suche

• Forscher*innen.
• Institutionen.
• Projekte.
• Publikationen.
• Partner.
• Geldgeber.
• Ausstattung.
• Knowhow.
• Forschungsfelder.

Publikationen

Suchbegriffe: HYPERPARATHYROIDISM, . Treffer: 71

2023

Appelman-Dijkstra, NM; Pilz, S Approach to the Patient: Management of Parathyroid Diseases Across Pregnancy.
J Clin Endocrinol Metab. 2023; 108(6):1505-1513 Doi: 10.1210/clinem/dgac734 (- Case Report)
Web of Science PubMed FullText FullText_MUG

 

Egli-Spichtig, D; Hamid, AK; Arroyo, EMP; Ketteler, M; Wiecek, A; Rosenkranz, AR; Pasch, A; Lorenz, H; Hellmann, B; Karus, M; Ammer, R; Rubio-Aliaga, I; Wagner, CA Intact FGF23 predicts serum phosphate improvement after combined nicotinamide and phosphate binder treatment in hemodialysis patients
CLIN KIDNEY J. 2023; Doi: 10.1093/ckj/sfad040
Web of Science FullText FullText_MUG

 

Herteux, J; Geiger, SJ; Starchl, C; Windisch, J; Lerchl, T; Tmava-Berisha, A; Wünsch, G; Eller, K; Fahrleitner-Pammer, A; Amrein, K Hospitalizations, emergency room visits and causes of death in 198 patients with permanent hypoparathyroidism - a retrospective Austrian study (2005-2022).
Endocr Connect. 2023; Doi: 10.1530/EC-22-0533 [OPEN ACCESS]
PubMed FullText FullText_MUG

 

2022

Bollerslev, J; Rejnmark, L; Zahn, A; Heck, A; Appelman-Dijkstra, NM; Cardoso, L; Hannan, FM; Cetani, F; Sikjær, T; Formenti, AM; Björnsdottir, S; Schalin-Jantti, C; Belaya, Z; Gibb, FW; Lapauw, B; Amrein, K; Wicke, C; Grasemann, C; Krebs, M; Ryhänen, EM; Makay, O; Minisola, S; Gaujoux, S; Bertocchio, JP; Hassan-Smith, ZK; Linglart, A; Winter, EM; Kollmann, M; Zmierczak, HG; Tsourdi, E; Pilz, S; Siggelkow, H; Gittoes, NJ; Marcocci, C; Kamenicky, P, , 2021, PARAT, Working, Group European Expert Consensus on Practical Management of Specific Aspects of Parathyroid Disorders in Adults and in Pregnancy: Recommendations of the ESE Educational Program of Parathyroid Disorders.
Eur J Endocrinol. 2022; 186(2):R33-R63 Doi: 10.1530/EJE-21-1044 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Hoppner, J; Sinningen, K; Raimann, A; Obermayer-Pietsch, B; Grasemann, C Disorders of the Calcium Sensing Signaling Pathway: From Familial Hypocalciuric Hypercalcemia (FHH) to Life Threatening Conditions in Infancy
J CLIN MED. 2022; 11(9): 2595 Doi: 10.3390/jcm11092595 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2021

Nazerani Hooshmand, T; Pernthaler, B; Szurian, K; Pau, M; Aigner, RM 18F-FDG PET/CT in the Hyperparathyroidism-Jaw-Tumor Syndrome.
Clin Nucl Med. 2021; 46(6):497-498 Doi: 10.1097/RLU.0000000000003625
Web of Science PubMed FullText FullText_MUG

 

2019

Amrein, K; Dobnig, H Primary hyperparathyroidism. Three interesting case reports and innovations in diagnosis and therapy
AUST J CLIN ENDOCR M. 2019; 12(2): 50-54. Doi: 10.1007/s41969-019-0063-x [OPEN ACCESS]
Web of Science FullText FullText_MUG

 

Bollerslev, J; Schalin-Jantti, C; Rejnmark, L; Siggelkow, H; Morreau, H; Thakker, RV; Sitges-Serra, A; Cetani, F; Marcocci, C; PARAT Workshop Group MANAGEMENT OF ENDOCRINE DISEASE: Unmet therapeutic, educational and scientific needs in parathyroid disorders.
EUR J ENDOCRINOL. 2019; 181(3): P1-P19. Doi: 10.1530/EJE-19-0316 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2018

Beheshti, M; Hehenwarter, L; Paymani, Z; Rendl, G; Imamovic, L; Rettenbacher, R; Tsybrovskyy, O; Langsteger, W; Pirich, C ¹⁸F-Fluorocholine PET/CT in the assessment of primary hyperparathyroidism compared with ^99mTc-MIBI or ^99mTc-tetrofosmin SPECT/CT: a prospective dual-centre study in 100 patients.
Eur J Nucl Med Mol Imaging. 2018; 45(10): 1762-1771. Doi: 10.1007/s00259-018-3980-9 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Friedl, C; Zitt, E Role of etelcalcetide in the management of secondary hyperparathyroidism in hemodialysis patients: a review on current data and place in therapy.
DRUG DES DEV THER. 2018; 12: 1589-1598. Doi: 10.2147/DDDT.S134103 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Littbarski, SA; Kaltenborn, A; Gwiasda, J; Beneke, J; Arelin, V; Schwager, Y; Stupak, JV; Marcheel, IL; Emmanouilidis, N; Jäger, MD; Scheumann, GFW; Klempnauer, J; Schrem, H Timing of parathyroidectomy in kidney transplant candidates with secondary hyperparathryroidism: effect of pretransplant versus early or late post-transplant parathyroidectomy.
Surgery. 2018; 163(2): 373-380. Doi: 10.1016/j.surg.2017.10.016
Web of Science PubMed FullText FullText_MUG

 

Pilz, S; Trummer, C; Verheyen, N; Schwetz, V; Pandis, M; Aberer, F; Grübler, MR; Meinitzer, A; Bachmann, A; Voelkl, J; Alesutan, I; Catena, C; Sechi, LA; März, W; Obermayer-Pietsch, B; Tomaschitz, A Mineralocorticoid Receptor Blockers and Aldosterone to Renin Ratio: A Randomized Controlled Trial and Observational Data.
Horm Metab Res. 2018; 50(5):375-382 Doi: 10.1055/a-0604-3249 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Vlot, MC; den Heijer, M; de Jongh, RT; Vervloet, MG; Lems, WF; de Jonge, R; Obermayer-Pietsch, B; Heijboer, AC Clinical utility of bone markers in various diseases.
Bone. 2018; 114(7):215-225 Doi: 10.1016/j.bone.2018.06.011
Web of Science PubMed FullText FullText_MUG

 

Zittermann, A; Ernst, JB; Prokop, S; Fuchs, U; Dreier, J; Kuhn, J; Berthold, HK; Pilz, S; Gouni-Berthold, I; Gummert, JF Vitamin D supplementation and bone turnover in advanced heart failure: the EVITA trial.
Osteoporos Int. 2018; 29(3): 579-586. Doi: 10.1007/s00198-017-4312-9
Web of Science PubMed FullText FullText_MUG

 

2017

Frauscher, B; Artinger, K; Kirsch, AH; Aringer, I; Moschovaki-Filippidou, F; Kétszeri, M; Schabhüttl, C; Rainer, PP; Schmidt, A; Stojakovic, T; Fahrleitner-Pammer, A; Rosenkranz, AR; Eller, P; Eller, K A New Murine Model of Chronic Kidney Disease-Mineral and Bone Disorder.
Int J Endocrinol. 2017; 2017(3):1659071-1659071 Doi: 10.1155/2017/1659071 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Friedl, C; Reibnegger, G; Kramar, R; Zitt, E; Pilz, S; Mann, JFE; Rosenkranz, AR Mortality in dialysis patients with cinacalcet use: A large observational registry study.
Eur J Intern Med. 2017; 42(5-6):89-95 Doi: 10.1016/j.ejim.2017.05.002
Web of Science PubMed FullText FullText_MUG

 

Friedl, C; Zitt, E Vitamin D prohormone in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease.
Int J Nephrol Renovasc Dis. 2017; 10(9):109-122 Doi: 10.2147/IJNRD.S97637 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Gwiasda, J; Kaltenborn, A; Müller, JA; Serttas, M; Scheumann, GW; Schrem, H; Jäger, MD Ultrasound-based scores as predictors for nodular hyperplasia in patients with secondary hyperparathyroidism: a prospective validation study.
Langenbecks Arch Surg. 2017; 402(2): 295-301. Doi: 10.1007/s00423-016-1546-5
Web of Science PubMed FullText FullText_MUG

 

Jäger, MD; Serttas, M; Beneke, J; Müller, JA; Schrem, H; Kaltenborn, A; Ramackers, W; Ringe, BP; Gwiasda, J; Tränkenschuh, W; Klempnauer, J; Scheumann, GFW Risk-factors for nodular hyperplasia of parathyroid glands in sHPT patients.
PLoS One. 2017; 12(10): e0186093-e0186093. Doi: 10.1371/journal.pone.0186093 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Obermüller, N; Rosenkranz, AR; Müller, HW; Hidde, D; Veres, A; Decker-Burgard, S; Weisz, I; Geiger, H Long-Term Therapy Outcomes When Treating Chronic Kidney Disease Patients with Paricalcitol in German and Austrian Clinical Practice (TOP Study).
Int J Mol Sci. 2017; 18(10): Doi: 10.3390/ijms18102057 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Pronai, W; Rosenkranz, AR; Bock, A; Klauser-Braun, R; Jäger, C; Pendl, G; Hemetsberger, M; Lhotta, K Management of secondary hyperparathyroidism: practice patterns and outcomes of cinacalcet treatment with or without active vitamin D in Austria and Switzerland - the observational TRANSIT Study.
Wien Klin Wochenschr. 2017; 129(9-10):317-328 Doi: 10.1007/s00508-016-1153-z [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Robinson-Cohen, C; Lutsey, PL; Kleber, ME; Nielson, CM; Mitchell, BD; Bis, JC; Eny, KM; Portas, L; Eriksson, J; Lorentzon, M; Koller, DL; Milaneschi, Y; Teumer, A; Pilz, S; Nethander, M; Selvin, E; Tang, W; Weng, LC; Wong, HS; Lai, D; Peacock, M; Hannemann, A; Völker, U; Homuth, G; Nauk, M; Murgia, F; Pattee, JW; Orwoll, E; Zmuda, JM; Riancho, JA; Wolf, M; Williams, F; Penninx, B; Econs, MJ; Ryan, KA; Ohlsson, C; Paterson, AD; Psaty, BM; Siscovick, DS; Rotter, JI; Pirastu, M; Streeten, E; März, W; Fox, C; Coresh, J; Wallaschofski, H; Pankow, JS; de Boer, IH; Kestenbaum, B Genetic Variants Associated with Circulating Parathyroid Hormone.
J Am Soc Nephrol. 2017; 28(5):1553-1565 Doi: 10.1681/ASN.2016010069 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Verheyen, N; Fahrleitner-Pammer, A; Belyavskiy, E; Gruebler, MR; Dimai, HP; Amrein, K; Ablasser, K; Martensen, J; Catena, C; Pieske-Kraigher, E; Colantonio, C; Voelkl, J; Lang, F; Alesutan, I; Meinitzer, A; März, W; Brussee, H; Pieske, B; Pilz, S; Tomaschitz, A Relationship between bone turnover and left ventricular function in primary hyperparathyroidism: The EPATH trial.
PLoS One. 2017; 12(4):e0173799-e0173799 Doi: 10.1371/journal.pone.0173799 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Verheyen, N; Grübler, MR; Meinitzer, A; Trummer, C; Schwetz, V; Amrein, K; Dimai, HP; März, W; Catena, C; von Lewinski, D; Voelkl, J; Alesutan, I; Fahrleitner-Pammer, A; Brussee, H; Pilz, S; Tomaschitz, A Effect of eplerenone on markers of bone turnover in patients with primary hyperparathyroidism - The randomized, placebo-controlled EPATH trial.
Bone. 2017; 105(5):212-217 Doi: 10.1016/j.bone.2017.08.030
Web of Science PubMed FullText FullText_MUG

 

Verheyen, N; Meinitzer, A; Grübler, MR; Ablasser, K; Kolesnik, E; Fahrleitner-Pammer, A; Belyavskiy, E; Trummer, C; Schwetz, V; Pieske-Kraigher, E; Voelkl, J; Alesutan, I; Catena, C; Sechi, LA; Brussee, H; Lewinski, DV; März, W; Pieske, B; Pilz, S; Tomaschitz, A Low-grade inflammation and tryptophan-kynurenine pathway activation are associated with adverse cardiac remodeling in primary hyperparathyroidism: the EPATH trial.
Clin Chem Lab Med. 2017; 55(7):1034-1042 Doi: 10.1515/cclm-2016-1159
Web of Science PubMed FullText FullText_MUG

 

Wetzel, J; Pilz, S; Grübler, MR; Fahrleitner-Pammer, A; Dimai, HP; von Lewinski, D; Kolesnik, E; Perl, S; Trummer, C; Schwetz, V; Meinitzer, A; Belyavskiy, E; Völkl, J; Catena, C; Brandenburg, V; März, W; Pieske, B; Brussee, H; Tomaschitz, A; Verheyen, ND Plasma parathyroid hormone and cardiovascular disease in treatment-naive patients with primary hyperparathyroidism: The EPATH trial.
J Clin Hypertens (Greenwich). 2017; 19(11):1173-1180 Doi: 10.1111/jch.13064 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2016

Amrein, K; Dimai, HP; Dobnig, H; Fahrleitner-Pammer, A Plasmapheresis and Osteoporosis: The Absence of Evidence Is Not the Evidence of Absence
J MINERAL. 2016; 23(2): 44-47. [OPEN ACCESS]
Web of Science

 

Haffner-Luntzer, M; Heilmann, A; Heidler, V; Liedert, A; Schinke, T; Amling, M; Yorgan, TA; Vom Scheidt, A; Ignatius, A Hypochlorhydria-induced calcium malabsorption does not affect fracture healing but increases post-traumatic bone loss in the intact skeleton.
J Orthop Res. 2016; 34(11): 1914-1921. Doi: 10.1002/jor.23221 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Tomaschitz, A; Verheyen, N; Meinitzer, A; Pieske, B; Belyavskiy, E; Brussee, H; Haas, J; März, W; Pieske-Kraigher, E; Verheyen, S; Ofner-Ziegenfuss, L; Hartaigh, BÓ; Schwetz, V; Aberer, F; Grübler, M; Lang, F; Alesutan, I; Voelkl, J; Gaksch, M; Horina, JH; Dimai, HP; Rus-Machan, J; Stiegler, C; Ritz, E; Fahrleitner-Pammer, A; Pilz, S Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: results from the EPATH randomized, placebo-controlled trial.
J Hypertens. 2016; 34(7):1347-56 Doi: 10.1097/HJH.0000000000000927
Web of Science PubMed FullText FullText_MUG

 

Verheyen, N; Fahrleitner-Pammer, A; Pieske, B; Meinitzer, A; Belyavskiy, E; Wetzel, J; Gaksch, M; Grübler, MR; Catena, C; Sechi, LA; Van, Ballegooijen, AJ; Brandenburg, VM; Scharnagl, H; Perl, S; Brussee, H; März, W; Pilz, S; Tomaschitz, A Parathyroid hormone, aldosterone-to-renin ratio and fibroblast growth factor-23 as determinants of nocturnal blood pressure in primary hyperparathyroidism: the eplerenone in primary hyperparathyroidism trial.
J Hypertens. 2016; 34(9):1778-86 Doi: 10.1097/HJH.0000000000001004 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2015

Pihlstrøm, H; Dahle, DO; Mjøen, G; Pilz, S; März, W; Abedini, S; Holme, I; Fellström, B; Jardine, AG; Holdaas, H Increased risk of all-cause mortality and renal graft loss in stable renal transplant recipients with hyperparathyroidism.
Transplantation. 2015; 99(2):351-359 Doi: 10.1097/TP.0000000000000583 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Tomaschitz, A; Verheyen, N; Gaksch, M; Meinitzer, A; Pieske, B; Kraigher-Krainer, E; Colantonio, C; März, W; Schmidt, A; Belyavskiy, E; Rus-Machan, J; van, Ballegooijen, AJ; Stiegler, C; Amrein, K; Ritz, E; Fahrleitner-Pammer, A; Pilz, S Homoarginine in patients with primary hyperparathyroidism.
Am J Med Sci. 2015; 349(4):306-11 Doi: 10.1097/MAJ.0000000000000419
Web of Science PubMed FullText FullText_MUG

 

Verheyen, N; Wetzel, J; Martensen, J; Belyavskiy, E; Schmidt, A; Colantonio, C; Catena, C; Gaksch, M; Grübler, MR; Kraigher-Krainer, E; Pieske, B; Meinitzer, A; Rus-Machan, J; Fahrleitner-Pammer, A; Pilz, S; Tomaschitz, A 9B.05: ASSOCIATION OF PLASMA PARATHYROID HORMONE WITH NIGHTTIME BLOOD PRESSURE IN PRIMARY HYPERPARATHYROIDISM-THE "EPLERENONE IN PRIMARY HYPERPARATHYROIDISM" TRIAL.
J Hypertens. . 2015; 33 Suppl 1(10):e121-e121. Doi: 10.1097/01.hjh.0000467677.24307.ad [Oral Communication]
Web of Science PubMed FullText FullText_MUG

 

2014

Jäger, MD; Emmanouilidis, N; Jackobs, S; Kespohl, H; Hett, J; Musatkin, D; Tränkenschuh, W; Schrem, H; Klempnauer, J; Scheumann, GF Presence of small parathyroid glands in renal transplant patients supports less-than-total parathyroidectomy to treat hypercalcemic hyperparathyroidism.
Surgery. 2014; 155(1): 22-32. Doi: 10.1016/j.surg.2013.06.011
Web of Science PubMed FullText FullText_MUG

 

Tomaschitz, A; Ritz, E; Pieske, B; Rus-Machan, J; Kienreich, K; Verheyen, N; Gaksch, M; Grübler, M; Fahrleitner-Pammer, A; Mrak, P; Toplak, H; Kraigher-Krainer, E; März, W; Pilz, S Aldosterone and parathyroid hormone interactions as mediators of metabolic and cardiovascular disease.
Metabolism. 2014; 63(1):20-31 Doi: 10.1016/j.metabol.2013.08.016 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2013

Kirsch, AH; Smaczny, N; Riegelbauer, V; Sedej, S; Hofmeister, A; Stojakovic, T; Goessler, W; Brodmann, M; Pilger, E; Rosenkranz, AR; Eller, K; Eller, P Regulatory T cells improve nephrocalcinosis but not dystrophic cardiac calcinosis in DBA/2 mice.
Am J Pathol. 2013; 183(2):382-390 Doi: 10.1016/j.ajpath.2013.04.012 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Tilz, H; Becker, JC; Legat, F; Schettini, AP; Inzinger, M; Massone, C Allopurinol in the treatment of acquired reactive perforating collagenosis.
An Bras Dermatol. 2013; 88(1):94-97 Doi: 10.1590/s0365-05962013000100012 (- Case Report) [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Verheyen, N; Pilz, S; Eller, K; Kienreich, K; Fahrleitner-Pammer, A; Pieske, B; Ritz, E; Tomaschitz, A Cinacalcet hydrochloride for the treatment of hyperparathyroidism.
Expert Opin Pharmacother. 2013; 14(6):793-806 Doi: 10.1517/14656566.2013.777041
Web of Science PubMed FullText FullText_MUG

 

2012

Osto, E; Fallo, F; Pelizzo, MR; Maddalozzo, A; Sorgato, N; Corbetti, F; Montisci, R; Famoso, G; Bellu, R; Lüscher, TF; Iliceto, S; Tona, F Coronary microvascular dysfunction induced by primary hyperparathyroidism is restored after parathyroidectomy.
Circulation. 2012; 126(9):1031-9 Doi: 10.1161/CIRCULATIONAHA.111.081307
Web of Science PubMed FullText FullText_MUG

 

Pilz, S; Kienreich, K; Drechsler, C; Ritz, E; Fahrleitner-Pammer, A; Gaksch, M; Meinitzer, A; März, W; Pieber, TR; Tomaschitz, A Hyperparathyroidism in patients with primary aldosteronism: cross-sectional and interventional data from the GECOH study.
J Clin Endocrinol Metab. 2012; 97(1):E75-9 Doi: 10.1210/jc.2011-2183 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Tomaschitz, A; Fahrleitner-Pammer, A; Pieske, B; Verheyen, N; Amrein, K; Ritz, E; Kienreich, K; Horina, JH; Schmidt, A; Kraigher-Krainer, E; Colantonio, C; Meinitzer, A; Pilz, S Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: a randomized, double-blind, placebo-controlled trial.
BMC Endocr Disord. 2012; 12(12):19-19 Doi: 10.1186/1472-6823-12-19 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Tomaschitz, A; Ritz, E; Pieske, B; Fahrleitner-Pammer, A; Kienreich, K; Horina, JH; Drechsler, C; März, W; Ofner, M; Pieber, TR; Pilz, S Aldosterone and parathyroid hormone: a precarious couple for cardiovascular disease.
Cardiovasc Res. 2012; 94(1):10-19 Doi: 10.1093/cvr/cvs092 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Wagner, D; Amrein, K; Dimai, HP; Kniepeiss, D; Tscheliessnigg, KH; Kornprat, P; Dobnig, H; Pieber, T; Fahrleitner-Pammer, A Ibandronate and calcitriol reduces fracture risk, reverses bone loss, and normalizes bone turnover after LTX.
Transplantation. 2012; 93(3):331-336 Doi: 10.1097/TP.0b013e31823f7f68 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2011

Eller, P; Eller, K; Kirsch, AH; Patsch, JJ; Wolf, AM; Tagwerker, A; Stanzl, U; Kaindl, R; Kahlenberg, V; Mayer, G; Patsch, JR; Rosenkranz, AR A murine model of phosphate nephropathy.
Am J Pathol. 2011; 178(5):1999-2006 Doi: 10.1016/j.ajpath.2011.01.024 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Liu, Z; Segawa, H; Aydin, C; Reyes, M; Erben, RG; Weinstein, LS; Chen, M; Marshansky, V; Fröhlich, LF; Bastepe, M Transgenic overexpression of the extra-large Gsα variant XLαs enhances Gsα-mediated responses in the mouse renal proximal tubule in vivo.
Endocrinology. 2011; 152(4):1222-1233 Doi: 10.1210/en.2010-1034 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Reiter, N; El-Shabrawi, L; Leinweber, B; Berghold, A; Aberer, E Calcinosis cutis Part I. Diagnostic pathway.
J AM ACAD DERMATOL. 2011; 65(1): 1-12. Doi: 10.1016/j.jaad.2010.08.038
Web of Science PubMed FullText FullText_MUG

 

Zitt, E; Jäger, C; Rosenkranz, AR; Eigner, M; Kodras, K; Kovarik, J; Graf, H; Pétavy, F; Horn, S; Watschinger, B Effective use of cinacalcet for the treatment of secondary hyperparathyroidism in Austrian dialysis patients--results of the Austrian cohort of the ECHO study.
Wien Klin Wochenschr. 2011; 123(1-2):45-52 Doi: 10.1007/s00508-010-1515-x
Web of Science PubMed FullText FullText_MUG

 

Zitt, E; Kirsch, AH; Haueis, M; Strasak, A; Neyer, U; Mayer, G; Rosenkranz, AR The PTH (1-84)/non-PTH (1-84) ratio is a risk factor for cardiovascular events in hemodialysis patients.
Clin Nephrol. 2011; 75(4):309-318 Doi: 10.5414/CNP75309 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2010

Fröhlich, LF; Mrakovcic, M; Steinborn, R; Chung, UI; Bastepe, M; Jüppner, H Targeted deletion of the Nesp55 DMR defines another Gnas imprinting control region and provides a mouse model of autosomal dominant PHP-Ib.
Proc Natl Acad Sci U S A. 2010; 107(20): 9275-9280. Doi: 10.1073/pnas.0910224107 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2009

Nawrot-Wawrzyniak, K; Varga, F; Nader, A; Roschger, P; Sieghart, S; Zwettler, E; Roetzer, KM; Lang, S; Weinkamer, R; Klaushofer, K; Fratzl-Zelman, N Effects of tumor-induced osteomalacia on the bone mineralization process.
Calcif Tissue Int. 2009; 84(4): 313-323. Doi: 10.1007/s00223-009-9216-z [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Weitere 50 Treffer anzeigen

↑ Seitenanfang / Navigation

© Med Uni Graz • Impressum